Identification and validation of inferior prognostic genes associated with immune signatures and chemotherapy outcome in acute myeloid leukemia.

Acute myeloid leukemia (AML) is a group of heterogeneous hematological malignancies. We identified key genes as and lncRNA through different bioinformatics tools. Furthermore, qPCR was performed to verify the expression level of essential genes in clinical samples. Retrospective research on 179 AML cases was used to investigate the relationship between the expression of and the characteristics of AML. The critical gene relationship with immune infiltration in AML was estimated. The clinical validation and prognostic investigation showed that , , and are highly expressed in AML ( < 0.001) and significantly associated with the overall survival in AML. Moreover, the retrospective research on 179 clinical cases showed that positive expression of is substantially related to AML classification ( < 0.001), higher count of white blood cells ( < 0.01), and poor chemotherapy outcome ( < 0.05). Furthermore, based on grouping as the high and low expression in TCGA-LAML profile, we found that genes in the highly expressed group are mainly involved in immune infiltration and inflammation-related signaling pathways. Finally, we discovered that the expression level of and lncRNA are not just closely related to the immune score and stromal score ( < 0.001) but also significantly positively correlated with various Immune signatures in AML ( < 0.001), indicating the association of these genes with immunosuppression in AML. The prediction of candidate drugs indicated that certain immunosuppressive drugs have potential therapeutic effects for AML. The critical genes could be used as potential biomarkers to evaluate the survival and prognosis of AML.